Skip to main content

Inhalant Addiction

  • 141 Accesses

Abstract

This chapter is divided into seven sections, beginning with a general overview of this group of substances, their definitions, and the current classification of the disorders associated with their use. This is followed by a description of prevalence, the groups of the population affected, and the patterns of use in different regions of the world. Particular attention is paid to use among vulnerable groups, to inhalant effects and consequences, the social determinants that underlie the problem, and opportunities for solution. These sections are followed by a brief overview of the evidence for prevention and treatment strategies currently in use. This chapter ends with a discussion on policies to address the problem.

Keywords

  • Inhalant
  • Effects
  • Special population
  • Recovery potential
  • Policy

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-030-36391-8_20
  • Chapter length: 26 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   109.00
Price excludes VAT (USA)
  • ISBN: 978-3-030-36391-8
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   139.99
Price excludes VAT (USA)
Hardcover Book
USD   179.99
Price excludes VAT (USA)

References

  1. Alcohol and other Drug Council of Australia, Policy Position, Inhalants. 2010. http://www.healthinfonet.ecu.edu.au/key-resources/organisations?oid=403.

  2. Alt RS, Morrissey RP, Gang MA, Hoffman RS, Schaumburg HH. Severe myeloneuropathy from acute high-dose nitrous oxide (N2O) abuse. J Emerg Med. 2011;41(4):378–80. https://doi.org/10.1016/j.jemermed.2010.04.020.

    CrossRef  Google Scholar 

  3. American Psychiatric Association. Guía de consulta de los criterios diagnósticos del dsm-5: American Psychiatric Publishing; 2014.

    Google Scholar 

  4. Audo I, El Sanharawi M, Vignal-Clermont C, Villa A, Morin A, Conrath J, Fompeydie D, Sahel JA, Gocho-Nakashima K, Goureau O, Paques M. Foveal damage in habitual poppers users. Arch Ophthalmol. 2011;129(6):703–8. https://doi.org/10.1001/archophthalmol.2011.6.

    CrossRef  Google Scholar 

  5. Bale AS, Meacham CA, Benignus VA, Bushnell PJ, Shafer TJ. Volatile organic compounds inhibit human and rat neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes. Toxicol Appl Pharmacol. 2005a;205(1):77–88.

    CAS  CrossRef  Google Scholar 

  6. Bale AS, Tu Y, Carpenter-Hyland EP, Chandler LJ, Woodward JJ. Alterations in glutamatergic and gabaergic ion channel activity in hippocampal neurons following exposure to the abused inhalant toluene. Neuroscience. 2005b;130(1):197–206.

    CAS  CrossRef  Google Scholar 

  7. Balster RL, Cruz SL, Howard MO, Dell CA, Cottler LB. Classification of abused inhalants. Addiction. 2009;104(6):878–82. https://doi.org/10.1111/j.1360-0443.2008.02494.x.

    CrossRef  Google Scholar 

  8. Bassiony M. Substance use disorders in Saudi Arabia: review article. J Subst Use. 2013;18(6):450–66. https://doi.org/10.3109/14659891.2011.606349.

    CrossRef  Google Scholar 

  9. Basu D, Jhirwal OP, Singh J, Kumar S, Mattoo SK. Inhalant abuse by adolescents: a new challenge for Indian physicians. Indian J Med Sci. 2004;58:245–9.

    Google Scholar 

  10. Beauvais F, Oetting ER. Indian youth and inhalants: an update. NIDA Res Monogr. 1988;85:34–48. Epidemiology of inhalants abuse: an update.

    CAS  Google Scholar 

  11. Becerra B, Ortega-Soto H, Torner C. Validez y reproductibilidad del examen cognoscitivo brebe (Mini-mental State Examination) en una unidad de cuidados especiales de un hospital psiquiátrico. Salud Mental. 1992;15(4):41–5.

    Google Scholar 

  12. Becerra Pino M, Calleja Olvera J, Lozano Dávila M, Sosa Ortiz A, Trujillo de los Santos Z. Guía de Consulta para el Médico de Primer Nivel de Atención Alteraciones de la Memoria en la Persona Adulta Mayor. Centro Nacional de Programas Preventivos y Control de Enfermedades. Secretaría de Salud; 2010

    Google Scholar 

  13. Beckstead MJ, Weiner JL, Eger EI 2nd, Gong DH, Mihic SJ. Glycine and gamma-aminobutyric acid(A) receptor function is enhanced by inhaled drugs of abuse. Mol Pharmacol. 2000;57(6):1199–205.

    CAS  Google Scholar 

  14. Boak A, Hamilton HA, Adalf EM, Mann RE. Drug use among Ontario students. 1977-2017. Highlights from the Ontario student drug use and Health Survey (OSDUHS) (CAMH Research Document Series No. 46) Toronto: Center for Addiction and Mental Health; 2017. Available at: https://www.camh.ca/-/media/files/pdf%2D%2D-osduhs/drug-use-among-ontario-students-1977-2017%2D%2D-detailed-findings-from-the-osduhs.pdf?la=en&hash=2B434CDAAD485834497E3B43F2264BDEB255F29F.

  15. Bobes J, Bascarán MT, Bobes-Bascarán MT, Carballo JL, Díaz Mesa EM, Flórez G, García Portilla MP, Sáiz PA. Valoración de la gravedad de la adicción: aplicación a la gestión clínica y monitorización de los tratamientos. Madrid: Delegación del Gobierno para el Plan Nacional sobre Drogas; 2007. Available at: http://www.fundacioncsz.org/ArchivosPublicaciones/214.pdf.

    Google Scholar 

  16. Borges G, Wang P, Medina-Mora ME, Lara C, Chiu W. Delay of first treatment of mental and substance use disorders in Mexico. Am J Public Health. 2007;97(9):1638–43.

    CrossRef  Google Scholar 

  17. Borne J, Riascos R, Cuellar H, Vargas D, Rojas R. Neuroimaging in drug and substance abuse part II: opioids and solvents. Top Magn Reson Imaging. 2005;16(3):239–45.

    CrossRef  Google Scholar 

  18. Bowen SE, Batis JC, Paez-Martinez N, Cruz SL. The last decade of solvent research in animal models of abuse: mechanistic and behavioral studies. Neurotoxicol Teratol. 2006;28(6):636–47.

    CAS  CrossRef  Google Scholar 

  19. Bowen SE. Two serious and challenging medical complications associated with volatile substance misuse: sudden sniffing death and fetal solvent syndrome. Subst Use Misuse. 2011;46(1):68–72. https://doi.org/10.3109/10826084.2011.580220.

    CrossRef  Google Scholar 

  20. Bowen SE, Cruz SL. Inhalants: addiction and toxic effects in the human. In: Madras B, Kuhar M, editors. The effects of drug abuse on the human nervous system, Book 2 in the Neuroscience-net master reference book series (ebook); 2012. Available at: http://neuroscience.com/books/book-2-effects-drug-abuse-human-nervous-system.

    Google Scholar 

  21. Chávez J, Villatoro J, Robles L, Bustos M, Moreno M, Olivia N, Fregoso D, Gómez G, Medina-Mora ME, Paredes A. Encuesta escolar sobre adicciones en el Estado de Jalisco 2012. Consejo Estatal contra las Adicciones de Jalisco. México: Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz; 2013.

    Google Scholar 

  22. Cruz SL, Mirshahi T, Thomas B, Balster RL, Woodward JJ. Effects of the abused solvent toluene on recombinant N-methyl-D-aspartate and non-N-methyl-D-aspartate receptors expressed in Xenopus oocytes. J Pharma Exp Therap. 1998;286(1):334–40.

    CAS  Google Scholar 

  23. Cruz SL, Orta-Salazar G, Gauthereau MY, Millan-Perez Pena L, Salinas-Stefanon EM. Inhibition of cardiac sodium currents by toluene exposure. Br J Pharmacol. 2003;140(4):653–60.

    CAS  CrossRef  Google Scholar 

  24. Cruz SL, Bowen, SE Inhalant abuse. In: Ubach MM, Mondragon-Ceballos R, editors. Neural mechanisms of action of drugs of abuse and natural reinforcers. (ISBN 978-81-308-0245-9) Pandalai, Managing editor, Research Signpost, Kerala, India; 2008. p. 181.

    Google Scholar 

  25. Cruz SL. The latest evidence in the neuroscience of solvent misuse: an article written for service providers. Subst Use Misuse. 2011;46(Suppl 1):62–7.

    CrossRef  Google Scholar 

  26. Cruz SL, Dominguez M. Misusing volatile substances for their hallucinatory effects: a qualitative pilot study with Mexican teenagers and a pharmacological discussion of their hallucinations. Subst Use Misuse. 2011;46(Suppl 1):84–94. https://doi.org/10.3109/10826084.2011.580222.

    CrossRef  Google Scholar 

  27. Cruz SL, Rivera-García MT, Woodward JJ. Review of toluene actions: clinical evidence, animal studies, and molecular targets. J Drug Alcohol Res. 2014;3:1–8. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4211428/.

    CrossRef  Google Scholar 

  28. Cruz SL. Inhalant misuse management. The experience in Mexico and a literature review. J Subst Use. 2018;23(5):485–91. https://doi.org/10.1080/14659891.2017.1405090.

    CrossRef  Google Scholar 

  29. Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet. 2012;379(9810):55–70. https://doi.org/10.1016/S0140-6736(11)61138-0.

    CrossRef  Google Scholar 

  30. Del Re AM, Dopico AM, Woodward JJ. Effects of the abused inhalant toluene on ethanol-sensitive potassium channels expressed in oocytes. Brain Res. 2006;1087(1):75–82.

    CrossRef  CAS  Google Scholar 

  31. Dell C, Ogborne A, Begin P. Youth residential solvent treatment program design: an examination of the role of program length and length of client stay. Ottawa: Canadian Center on Substance Abuse; 2003.

    Google Scholar 

  32. Dell D, Hopkins C. Residential volatile substance misuse treatment for indigenous youth in Canada. Subst Use Misuse. 2011;46(S1):107–13. https://doi.org/10.3109/10826084.2011.580225.

    CrossRef  Google Scholar 

  33. Dingwall KM, Cairney S. Recovery from central nervous system changes following volatile substance misuse. Subst Use Misuse. 2011;46(1):73–83. https://doi.org/10.3109/10826084.2011.580221.

    CrossRef  Google Scholar 

  34. Demyttenaere K, Bruffaerts R, Posada-Villa J, Gasquet I, Kovess V, Lepine J, Angermeyer MC, Bernert S, de Girolamo G, Morosini P, Polidori G, Kikkawa T, Kawakami N, Ono Y, Takeshima T, Uda H, Karam EG, Fayyad JA, Karam AN, Mneimneh ZN, Medina-Mora ME, Borges G, Lara C, de Graaf R, Ormel J, Gureje O, Shen Y, Huang Y, Zhang M, Alonso J, Haro JM, Vilagut G, Bromet EJ, Gluzman S, Webb C, Kessler RC, Merikangas KR, Anthony JC, Von Korff MR, Wang PS, Brugha TS, Aguilar-Gaxiola S, Lee S, Heeringa S, Pennell BE, Zaslavsky AM, Ustun TB, Chatterji S, World Mental Health Survey Consortium WHO. Prevalence, severity and unmet need for treatment of mental disorders in the World Health Organization World Mental Health (WMH) surveys. JAMA. 2004;291(21):2581–90.

    CrossRef  Google Scholar 

  35. Drug Enforcement Administration. Drugs of abuse. Inhalants. 2015 EDITION: a DEA resource guide. 2015. Available at: https://portal.ct.gov/-/media/DCF/Substance_Abuse/pdf/Inhalentspdf.pdf?la=en.

  36. Duncan JR, Lawrence AJ. Conventional concepts and new perspectives for understanding the addictive properties of inhalants. J Pharmacol Sci. 2013;122(4):237–43.

    CAS  CrossRef  Google Scholar 

  37. Echeverría C, Tavera S. Matlapa. Redes de atención para la infancia en situación de calle. México: Instituto Nacional de Desarrollo Social; 2007.

    Google Scholar 

  38. ESPAD. Report 2015. Results from the European School Survey Project on Alcohol and Other Drugs. European Monitoring Center for Drugs and Drug Addiction; 2016.

    Google Scholar 

  39. European Monitoring Center for Drugs and Drug Addiction. Country overview: Uzbekistan [Internet]. 2015. Available at: http://www.emcdda.europa.eu/publications/country-overviews/uz#gps.

  40. Filley CM, Halliday K, Kleinschmidt-DeMasters BK. The effects of toluene on the central nervous system. J Neuropathol Exp Neurol. 2004;63(1):1–12.

    CAS  CrossRef  Google Scholar 

  41. Folstein M, Folstein S, McHugh P. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.

    CAS  CrossRef  Google Scholar 

  42. Fundación SEARCH. Guía para profesionales sobre abuso de sustancias volátiles. Fundación Search Comunidad Europeas. 2002. Available at: http://www.lwl.org/ks-download/downloads/searchII/Solvents-Guide_span.pdf.

  43. Garland EL, Howard MO. Volatile substance misuse: clinical considerations, neuropsychopharmacology and potential role of pharmacotherapy in management. CNS Drugs. 2012;26(11):927–35. https://doi.org/10.1007/s40263-012-0001-6.

    CAS  CrossRef  Google Scholar 

  44. Gigengack R. “My body breaks. I take solution.” Inhalant use in Dheli as pleasure seeking at a cost. Int J Drug Policy. 2014;25(4):810–8. https://doi.org/10.1016/j.drugpo.2014.06.003.

    CrossRef  Google Scholar 

  45. Gutiérrez R, Vega L, Medina-Mora ME. La infancia “callejera” en México. In: Echeverría C, Tavera S, editors. Matlapa. Redes de atención para la infancia en situación de calle. 1st ed. México: nstituto Nacional de Desarrollo Social; 2007. pp.17–34.

    Google Scholar 

  46. Hannigan JH, Bowen SE. Reproductive toxicology and teratology of abused toluene. Syst Biol Reprod Med. 2010;56(2):184–200. https://doi.org/10.3109/19396360903377195.

    CAS  CrossRef  Google Scholar 

  47. Health Performance Framework. Health performance framework report. Determinants of Health. Drug and other substance use including inhalants. Australian Government. Department of the Prime Minister and Cabinet Aboriginal and Torres Strait Islander; 2014.

    Google Scholar 

  48. Hernandez-Avila CA, Ortega-Soto HA, Jasso A, Hasfura-Buenaga CA, Kranzler HR. Treatment of inhalant-induced psychotic disorder with carbamazepine versus haloperidol. Psychiatr Serv. 1998;49(6):812–5.

    CAS  CrossRef  Google Scholar 

  49. Hillabrant W, Woodis P, Navratil C, McKenzie J, Rhoades M. Inhalant abuse in Indian country. Indian Health Service. Support Services International, Inc.; 2001

    Google Scholar 

  50. Howard MO, Bowen SE, Garland EL, Perron BE, Vaughn MG. Inhalant use and inhalant use disorders in the United States. Addict Sci Clin Pract. 2011;6(1):18–31.

    Google Scholar 

  51. Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Instituto Nacional de Salud Pública, Comisión Nacional Contra las Adiciones, Secretaría de Salud. Encuesta Nacional de Drogas, Alcohol y Tabaco 2016–2017: Reporte de drogas. Ciudad de México: INRF; 2017.

    Google Scholar 

  52. Johnston LD, O’Malley PM, Bachman JG. Monitoring the future national survey results on drug use, 1975–2002. Volume I: secondary school students (NIH Publication no. 03-5375) Bethesda: National Institute on Drug Abuse; 2003.

    Google Scholar 

  53. Johnston LD, Miech RA, O’Malley PM, Bachman JG, Schulenberg JE, Patrick ME. Monitoring the future national survey results on drug use 1975–2018: overview, key findings on adolescent drug use. Ann Arbor: Institute for Social Research, University of Michigan; 2019.

    CrossRef  Google Scholar 

  54. Konghom S, Verachai V, Srisurapanont M, Suwanmajo S, Ranuwattananon A, Kimsongneun N, Uttawichai K. Treatment for inhalant dependence and abuse. Cochrane Database Syst Rev. 2010;8(12) https://doi.org/10.1002/14651858.CD007537.pub2.

  55. Koposov R, Stickley A, Ruchkin V. Inhalant use in adolescents in northern Russia. Soc Psychiatry Psychiatr Epidemiol. 2018;53(7):709–16. https://doi.org/10.1007/s00127-018-1524-z.

    CrossRef  Google Scholar 

  56. Kurtzman T, Otsuka K, Wahl R. Inhalant abuse by adolescents. J Adolesc Health. 2001;28(3):170–80.

    CAS  CrossRef  Google Scholar 

  57. Leal H, Mejía L, Gómez I, Salinas de Valle O. Estudio naturalístico sobre el fenómeno del consumo de inhalantes en niños de la Ciudad de México. Contreras C (comp) En Inhalación Voluntaria de Disolventes Industriales, Trillas, México; 1977. p. 442–459.

    Google Scholar 

  58. Lin RJ, Chen HF, Chang YC, Su JJ. Subacute combined degeneration caused by nitrous oxide intoxication: case reports. Acta Neurol Taiwanica. 2011;20(2):129–37.

    Google Scholar 

  59. Lubman DI, Yücel M, Lawrence AJ. Inhalant abuse among adolescents: neurobiological considerations. Br J Pharmacol. 2008;154(2):316–26. https://doi.org/10.1038/bjp.2008.76.

    CAS  CrossRef  Google Scholar 

  60. McLellan AT, Luborsky L, O’Brien CP, Woody GE. An improved evaluation instrument for substance abuse patients: the addiction severity index. J Nerv Ment Dis. 1980;168(1):26–33.

    CAS  CrossRef  Google Scholar 

  61. MacLean S. Global selves: marginalised young people and aesthetic reflexivity in inhalant drug use. J Youth Stud. 2007;10(4):399–418. https://doi.org/10.1080/13676260701360691.

    CrossRef  Google Scholar 

  62. MacLean S, Cameron J, Harney A, Lee NK. Psychosocial therapeutic interventions for volatile substance use: a systematic review. Addiction. 2012;107(2):278–88. https://doi.org/10.1111/j.1360-0443.2011.03650.x.

    CrossRef  Google Scholar 

  63. Medina-Mora ME, Berenzon S. Epidemiology of inhalant abuse in Mexico. NIDA Res Monogr. 1995;148:136–74.

    CAS  Google Scholar 

  64. Medina-Mora ME, Gutiérrez R, Vega L. What happened to street kids? An analysis of the Mexican experience. Subst Use Misuse. 1997;32(3):293–316.

    CAS  CrossRef  Google Scholar 

  65. Medina-Mora ME, Real T. Epidemiology of inhalant use. Curr Opin Psychiatry. 2008;21(3):247–51. https://doi.org/10.1097/YCO.0b013e3282fc9875.

    CrossRef  Google Scholar 

  66. Medina-Mora ME, Vilatoro J, Fleiz C, Domínguez M, Cruz S. Challenges to neuroscience and public policy derived from new trends and patterns of inhalant misuse. J Int Drug Abuse Res Soc. 2014;3:1–8. https://doi.org/10.4303/jdar/235842.

  67. Medina-Mora ME, Rafful C, Villatoro J, Robles NO, Bustos M, Moreno M. Diferencias sociodemográficas entre usuarios de inhalables, usuarios de otras drogas y adolescents no consumidores en una muestra Mexicana de estudiantes. Rev Int Inv Adicciones. 2015;1(1):6–15. https://doi.org/10.28931/riiad.2015.1.02.

  68. Mesquita AM, de Andrade AG, Anthony JC. Use of the inhalant lança by Brazilian medical students. Subst Use Misuse. 1988;33(8):1667–80.

    CrossRef  Google Scholar 

  69. Misra LK, Kofoed L, Fuller W. Treatment of inhalant abuse with risperidone. J Clin Psych. 1999;60(9):620.

    CAS  CrossRef  Google Scholar 

  70. Mustonen A, Niemelä S, McGrath JJ, Murray GK, Nordström T, Mäki P, Miettunen J, Scott JG. Adolescent inhalant use and psychosis risk - a prospective longitudinal study. Schizophr Res. 2018;201:360–6. https://doi.org/10.1016/j.schres.2018.05.013.

    CrossRef  Google Scholar 

  71. National Inhalant Prevention Coalition. News briefs: CADCA announces National Leadership Forum; Press Conference Marks New Inhalant PSA & Survey. 1997.

    Google Scholar 

  72. National Institute of Drug Abuse. Inhalant abuse among children and adolescents: consultation on building an international research. 2005.

    Google Scholar 

  73. National Institute of Drug Abuse. The science of drug abuse. 2012. Available at: http://www.drugabuse.gov/drugs-abuse/inhalants.

  74. Organization of American States, Inter American Drug Abuse Control Commission. (OEA/CICAD). Report on drug use in the Americas 2019. Washington, DC: Inter American Drug Abuse Control Commission; 2019. Available at: http://www.cicad.oas.org/oid/Report%20on%20Drug%20Use%20in%20the%20Americas%202019.pdf.

  75. Ortiz A, Domínguez M, Palomares G. Solvent inhalants use in the San Judas Tadeo feast. Salud Mental. 2015;38(6):423–8. https://doi.org/10.17711/SM.0185-3325.2015.057.

    CrossRef  Google Scholar 

  76. Perron BE, Howard MO. Perceived risk of harm and intentions of future inhalant use among adolescent inhalant users. Drug Alcohol Depend. 2008;97(1–2):185–9. https://doi.org/10.1016/j.drugalcdep.2008.04.005.

    CrossRef  Google Scholar 

  77. Perron B, Mowbray O, Bier S, Vaughn M, Krentzman A, Howard M. Service use and treatment barriers among inhalant users. J Psychoactive Drugs. 2011;43(1):69–75. https://doi.org/10.1080/02791072.2011.566504.

    CrossRef  Google Scholar 

  78. Peters RH, Peyton E. Guideline for drug courts on screening and assessment. Prepared for the American University, Justice Programs Office, in association with the U.S. Department of Justice, Office of Justice Programs, Drug Courts Program Office. 1998. Available at: https://www.ncjrs.gov/pdffiles1/bja/171143.pdf.

  79. Poznyak V, Reed GM, Medina-Mora ME. Aligning the ICD-11 classification of disorders due to substance use with global service needs. Epidemiol Psychiatr Sci. 2018;27(3):212–8. https://doi.org/10.1017/S2045796017000622.

    CAS  CrossRef  Google Scholar 

  80. Ridenour TA, Halliburton AE, Bray BC. Does DSM-5 nomenclature for inhalant use disorder improve upon DSM-IV? Psychol Addict Behav. 2015;29(1):211–7. https://doi.org/10.1037/adb0000007.

    CrossRef  Google Scholar 

  81. Rodgers D. Youth gangs and violence in Latin America and the Caribbean, A literature survey. LCR Sustainable development working paper No.4. Washington DC: World Bank; 1999

    Google Scholar 

  82. Roy E, Leclerc P, Cédras L, Weber A, Claessens C, Boivin J. HIV incidence among street youth in Montreal, Canada. AIDS. 2003;17:1071–5.

    CrossRef  Google Scholar 

  83. Sakai JT, Hall SK, Mikulich-Gilbertson SK, Crowley TJ. Inhalant use, abuse, and dependence among adolescent patients: commonly comorbid problems. J Am Acad Child Adolesc Psychiatry. 2004;43(9):1080–8.

    CrossRef  Google Scholar 

  84. SAMHSA. The CBHSQ Report. Understanding adolescent inhalant use. National Survey on Drug Use and Health. 2017. Available at: https://www.samhsa.gov/data/sites/default/files/report_3095/ShortReport-3095.html.

  85. Sanchez Z, Noto A, Anthony J. Social rank and inhalant drug use: the case of lança perfume use in São Paulo, Brazil. Drug Alcohol Depend. 2012;131(1–2):92–9. https://doi.org/10.1016/j.drugalcdep.2012.12.001.

    CrossRef  Google Scholar 

  86. Secretaría de Salud Sistema de Vigilancia Epidemiológica de las Adicciones (SISVEA). Informe 2011. Secretaría de Salud. Subsecretaría de Prevención y Promoción de la Salud. México: Dirección General de Epidemiología; 2016

    Google Scholar 

  87. Shafer TJ, Bushnell PJ, Benignus VA, Woodward JJ. Perturbation of voltage-sensitive Ca2+ channel function by volatile organic solvents. J Pharma Expe Therapeutics. 2005;315(3):1109–18.

    CAS  CrossRef  Google Scholar 

  88. Sharp CW, Rosenber N, Beauvais F. Inhalant- related disorders. In: Tasman A, Kay J, Lieberman JA, First MB, Maj M, editors. Psychiatry. 3rd ed. New Jersey: John Wiley & Sons: 2008. p. 1127–48.

    Google Scholar 

  89. Shen YC. Treatment of inhalant dependence with lamotrigine. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(3):769–71.

    CAS  CrossRef  Google Scholar 

  90. Shimane T. Annual Report 2015 Nationwide General Population Survey on Drug Use in Japan. Health and Labour Sciences Research Grants 2015. Research on Regulatory Science of Pharmaceuticals and Medical Devices. H27-Iyaku A-Ippan-001 (2017).

    Google Scholar 

  91. Spiller HA. Epidemiology of volatile substance abuse (VSA) cases reported to US poison centers. Am J Drug Alcohol Abuse. 2004;30(1):155–65.

    CrossRef  Google Scholar 

  92. Swaim RC, Stanley LR. Substance use among American Indian youths on reservations compared with a National Sample of US adolescents. JAMA Netw Open. 2018; https://doi.org/10.1001/jamanetworkopen.2018.0382.

  93. Takagi M, Yücel M, Lubman D. The dark side of sniffing: paint colour affects intoxication experiences among adolescent inhalant users. Drug Alcohol Rev. 2010;29:452–5. https://doi.org/10.1111/j.1465-3362.2009.00162.x.

    CrossRef  Google Scholar 

  94. Trotter R, Rolf J, Baldwin L. Cultural models for inhalant abuse among Navajo youth. Drugs Society. 1997;10(1–2):39–59.

    CrossRef  Google Scholar 

  95. United Nations. Informe de la Junta Internacional de Fiscalización de Estupefacientes correspondiente a 2017. Viena: United Nations; 2018.

    Google Scholar 

  96. Vega L, Rendón A, Gutiérrez R, Villatoro J, Vargas A, Juárez A, Severiano E, Sánchez V, Trejo S. Estudio sobre patrones de consumo de sustancias psicoactivas en población indígena residente y originaria de la ciudad de México. México: INP-IAPA; 2015.

    Google Scholar 

  97. Verma R, Balhara YPS, Dhawan A. Inhalant abuse: an exploratory study. Psychiatry J. 2011;20(2):103–6. https://doi.org/10.4103/0972-6748.102493.

    CrossRef  Google Scholar 

  98. Villatoro J, Gaytán F, Moreno M, Gutiérrez ML, Olivia N, Bretón M, López MS, Bustos M, Medina-Mora ME. Consumo de Alcohol, Tabaco y otras Drogas en la Ciudad de México. Medición 2009. México: Instituto Nacional de Psiquiatria Ramón de la Fuente; 2010.

    Google Scholar 

  99. Villatoro J, Medina-Mora ME, Fleiz C, Moreno M, Oliva R, Bustos A, Fregoso D, Gutiérrez ML, Amador N. El consumo de drogas en México: Resultados de la Encuesta Nacional de Adicciones, 2011. Salud Mental. 2012;34:447–57.

    CrossRef  Google Scholar 

  100. Villatoro J, Medina-Mora ME, Martín del Campo R, Fregoso D, Bustos M, Reséndiz E, Mujica R, Bretón M, Soto I, Cañas V. El consumo de drogas en estudiantes de México: tendencias y magnitud del problema. Salud Mental. 2016;39(4):193–203.

    CrossRef  Google Scholar 

  101. Virginia Department of Education. Inhalant abuse prevention: staff education and student curriculum. Richmond: Division of Special Education and Student Services; 2007.

    Google Scholar 

  102. Wang RJ, Wang YT, Ma J, Liu MX, Su MF, Lian Z, Shi J, Lu L, Bao YP. Substance use among young people in China: a systematic review and meta-analysis. Lancet. 2017a;390(14):01. https://doi.org/10.1016/S0140-6736(17)33152-5.

    CrossRef  Google Scholar 

  103. Wang X, Li Y, Wu Z, Tang Z, Reilly KH, Nong Q. Nitrite inhalant use and HIV infection among Chinese men who have sex with men in 2 large cities in China. J Addict Med. 2017b;11(6):468–74. https://doi.org/10.1097/ADM.0000000000000347.

    CrossRef  Google Scholar 

  104. White V, Hayman J. Australian Secondary Students’ Use of Over-the-Counter and Illicit Substances in 2002. Canberra: Australian Government Department of Health and Ageing; 2004. National Drug Strategy Monograph series no.56.

    Google Scholar 

  105. Williams J, Storck M, and the Committee on Substance Abuse and Committee on Native American Child Health Pediatrics 2007; 119–10009. https://doi.org/10.1542/peds.2007-0470. http://pediatrics.aappublications.org/content/119/5/1009.full.html.

  106. World Bank. Crimen y Violencia en Centroamérica Un Desafío para el Desarrollo. Washington DC: Banco Mundial; 2011. www.bancomundial.org.lac.

    Google Scholar 

  107. World Drug Report. Global overview of drug demand and supply. Latest trends, cross-cutting issues. United Nations publication, Sales No. E.18.XI.9. 2018. Available at: https://www.unodc.org/wdr2018/prelaunch/WDR18_Booklet_2_GLOBAL.pdf.

  108. Wu LT, Howard MO. Psychiatric disorders in inhalant users: results from The national epidemiologic survey on alcohol and related conditions. Drug Alcohol Depend. 2007;88(2–3):146–55. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1934509&tool=pmcentrez&rendertype=abstract.

    CrossRef  Google Scholar 

  109. Yucel M, Takagi M, Walterfang M, Lubman DI. Toluene misuse and long-term harms: a systematic review of the neuropsychological and neuroimaging literature. Neurosci Biobehav Rev. 2008;32(5):910–26. https://doi.org/10.1016/j.neubiorev.2008.01.006.

    CAS  CrossRef  Google Scholar 

  110. Zakocs RC, Edwards EM. What explains community coalition effectiveness?: a review of the literature. Am J Prev Med. 2006;30(4):351–61.

    CrossRef  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Verify currency and authenticity via CrossMark

Cite this chapter

Real, T., Cruz, S.L., Medina-Mora, M.E., Robles, R., González, H. (2021). Inhalant Addiction. In: el-Guebaly, N., Carrà, G., Galanter, M., Baldacchino, A.M. (eds) Textbook of Addiction Treatment. Springer, Cham. https://doi.org/10.1007/978-3-030-36391-8_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-36391-8_20

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-36390-1

  • Online ISBN: 978-3-030-36391-8

  • eBook Packages: MedicineMedicine (R0)